Amylin gains after panel rejection

AMLN was up $0.05 to $7.99 on 17.1 million shares on Friday following Thursday's FDA negative panel vote on its Symlin pramlintide, in which the Endocrinologic and Metabolic Drugs Advisory Committee v...